Our objective was to investigate potential synergies of MLN4924 with other NF-kB-targeting agents for the treatment of CLL and elucidate the mechanisms of action underlying this pathway regulation. The gene discussed is NFKB1; the disease is B-cell chronic lymphocytic leukemia.